Furthermore, elevated circulating levels of E-cadherin fragmentation products have been reported to correlate with disease progression in patients with prostate cancer, providing a platform for non-invasive monitoring of tumor E-cadherin levels during treatment [39]. This evidence concerns the gene CDH1 and prostate carcinoma.